TP53 and hepatocellular carcinoma: ctDNA mutation analysis of 26 advanced HCC patients also showed that TERT C228T and TP53 mutations were at higher levels, so 77 % of the patients showed C228T mutation in the TERT promoter (Ge et al., 2021[56]).